Recommended Pages at plexxikon.com
Daiichi Sankyo To Acquire Plexxikon
plexxikon.com — “Plexxikon has utilized its proprietary discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including cardio-renal disease, CNS, inflammation, metabolic disease and oncology.” View full resource at plexxikon.com
Most Recently Shared on February 28, 2011 at 11:39 pm By:
Luke Timmerman Health Communicator
Berkeley, CA-based Plexxikon, maker of melanoma drug, bought by Daiichi Sankyo for $805M upfront. More to come. http://bit.ly/h2vovj
Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
plexxikon.com — “Plexxikon has utilized its proprietary discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including cardio-renal disease, CNS, inflammation, metabolic disease and oncology.” View full resource at plexxikon.com
Most Recently Shared on January 20, 2011 at 2:49 pm By:
Thomas J Reid MD PhD Hematologist, Physician, Doctor, PhD, Internist, and Oncologist
Melanoma, metastatic: inhibitor of mutated BRAF improves survival in phase III trial http://bit.ly/hkNVJQ
